Pancreatic Cancer Epidemiology Analysis by Stage, Sex & Age Group
Download the research sample at: https://www.pharmaproff.com/request-sample/1235
In general, advanced pancreatic cancer can present symptoms like nausea, vomiting, weight loss, jaundice, bloating, abdominal pain, and dyspepsia. Moreover, 70% of patients present diabetes mellitus, with a history of less than two years. In addition, poor prognosis of pancreatic cancer is attributed to the high incidence of metastasis, leading to the aggressive form of the disease combined with limited efficacy of systemic treatments.
Explore the research study at: https://www.pharmaproff.com/report/pancreatic-cancer-epidemiology-insights
The epidemiology study suggests that men are comparatively at higher risk of developing pancreatic cancer due to increased consumption of alcohol and smoking. Another risk factor associated with pancreatic cancer is age. It has been observed that maximum number of incident cases of this disease occur in the 75-85 age group.
According to the research findings, the global incidence of pancreatic cancer has increased substantially in the past decade. It is currently ranked as the 13th leading cause of cancer and is further on its way to become the fourth-leading cause of cancer related deaths in the U.S. by 2020.
Make enquiry before purchase at: https://www.pharmaproff.com/enquiry/1235
The incidence of pancreatic cancer is primarily driven by two factors - age and smoking. This disease is more common in elderly patients and people who smoke. Some research studies have also shown an increased incidence of this disease in patients suffering from diabetes or chronic pancreatitis.
The U.S. reported the highest number of incident cases amongst the seven major markets (7MM), followed by Japan during the period 2016-2028. Moreover, Germany is estimated to have the highest number of incidence cases, while Spain is anticipated to have the lowest number of cases amongst the European Union five (EU5) countries (i.e. U.K., France, Germany, Italy, and Spain).
The report provides detailed overview of pancreatic cancer, highlighting the causes, risk factors, classification, prognosis, pathophysiology, unmet medical needs, diagnosis, treatment options, and treatment algorithm for this disease. The report also provides comprehensive insights into trends of pancreatic cancer in the 7MM. Moreover, pancreatic cancer incidence for historical and forecasted periods has been analyzed in-depth and is further segmented into age-specific, sex- specific, and stage-specific data.
Toll-free: +1-888-778-7886 (USA/Canada)
Pharma Proff, is a frontline market intelligence and consulting solutions provider catering to the information and data needs of burgeoning sectors across the world, including pharmaceutical and healthcare. With meticulously curated research reports on the industry landscape, we empower companies in the healthcare and pharmaceutical sectors to make informed business decisions and base their marketing strategies with astuteness.
This release was published on openPR.
Permanent link to this press release:
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Pancreatic Cancer Epidemiology Analysis by Stage, Sex & Age Group here
News-ID: 1767858 • Views: 301
More Releases from Pharma Proff
Interleukin-6 (IL-6) Inhibitors Analysis, Clinical Trails and Developments
Interleukin-6 (IL-6) inhibitors currently exhibit a proliferating pipeline with 25+ therapeutic candidates. IL-6 is a cytokine encoded by IL-6 gene, which helps in the maturation of B cells and is actively involved in the inflammatory response. The IL-6 protein is primarily produced at the sites of acute and chronic inflammation, where it is secreted into the serum and brings a transcriptional inflammatory response through IL-6? receptor. This protein is assumed to
Retinitis Pigmentosa Therapeutics Analysis, Clinical Trials and Other Developmen …
Retinitis pigmentosa therapeutics currently exhibits a proliferating pipeline with 25+ therapeutic candidates. Retinitis pigmentosa (RP) is a group of hereditary disorders that lead to the breakdown and loss of cells in the retina. Mutation in genes encoding the proteins required by retinal cells for their proper functioning, results in occurrence of RP. The disease results in partial vision loss during the earlier stage of the disease, which may lead to complete
Probiotics Therapeutics -Pipeline Analysis 2018, Clinical Trials & Results, Pate …
Probiotics are live microorganisms that produces beneficial effects in human gut. Probiotics can be taken as a dietary supplement. They prevent diarrhoea and help to reduce the symptoms of irritable bowel syndrome. Download the sample report at: https://www.pharmaproff.com/request-sample/1189 Probiotics comprise of a variety of microorganisms belonging to the Lactobacillus and Bifidobacterium groups. The only yeast probiotic that has proven to be effective is Saccharomyces boulardii. According to researchers, probiotics are effective in
Niemann-Pick Disease Type C (NPC) Therapeutics Pipeline to Witness Significant G …
Niemann-Pick disease is divided into four main types: type A, type B, type C1, and type C2. These types are classified on the basis of genetic cause and signs and symptoms of the disease. NPC is identified as a rare genetic disorder in which the body is unable to transport cholesterol and lipids inside the cells. This causes accumulation of these substances within various tissues of the body. These substances
More Releases for Pancreatic
Pancreatic Cancer Therapy Market: Rise in Number of Patients Suffering with Panc …
Pancreatic cancer is one of the aggressive cancers that originate in the tissues of the pancreas and rapidly spreads to the nearby organs. Pancreatic cancer is the 12th most commonly occurring cancer in the world. According to the American Cancer Society, ~55,440 patients in the US are expected to be diagnosed with pancreatic cancer in 2018. Moreover, the ACS also reports that pancreatic cancer is the third leading cause of
Exocrine Pancreatic Insufficiency (EPI) Therapeutics- Pipeline Analysis
Exocrine pancreatic insufficiency (EPI) is the inability of pancreas to produce enough enzymes for the proper breakdown and absorption of nutrients. The common causes of EPI are damage to pancreas, inflammation of pancreas, pancreatic surgery, and inherited disorders like Crohn’s disease and celiac disease. Download the sample report at: https://www.pharmaproff.com/request-sample/1024 Some symptoms observed during EPI are pain or tenderness in belly, bad-smelling bowel movements, gas, diarrhea and feeling of fullness. EPI
Pancreatic Cancer Pipeline Review H1 2019
Pancreatic Cancer - Pipeline Review, H1 2017 Summary Publisher's latest Pharmaceutical and Healthcare disease pipeline guide Pancreatic Cancer - Pipeline Review, H1 2017, provides an overview of the Pancreatic Cancer (Oncology) pipeline landscape. Pancreatic cancer is a disease in which malignant (cancer) cells are found in the tissues of the pancreas. This is also called exocrine cancer. Signs and symptoms include upper abdominal pain that may radiate to back, yellowing of skin and
Pancreatic Cancer Pipeline Drugs Review H1 2017
Pancreatic Cancer Pipeline Review H1 2017 provides an overview of the Pancreatic Cancer (Oncology) therapeutics pipeline landscape. Pancreatic cancer is a disease in which malignant (cancer) cells are found in the tissues of the pancreas. Report provides comprehensive information on the therapeutics under development for Pancreatic Cancer (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide
Pancreatic Cancer Drug Pipeline Analysis
“Pancreatic Cancer Drug Pipeline Analysis” by PNS Pharma gives comprehensive insight on the various drug profiles being developed for the treatment of Pancreatic Cancer. Research report covers all the ongoing drug development in various phases. Each drug profiles include detailed information like: Originator, Owner, Collaborator, Technology Provider, Licensee, Development Phase, Development Indications, Mechanism of Action, Chemical Formula, Country of Development and detailed analysis on the development process. Insight for each
Exocrine Pancreatic Insufficiency Market 2013
Transparency Market Research has published a new market report titled, “Exocrine Pancreatic Insufficiency Market – Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2013 – 2023.” According to the report, the exocrine pancreatic insufficiency market is anticipated to expand at a CAGR of 8.3% from 2015 to 2023 to reach US$2.85 Bn by 2023. Browse the full Exocrine Pancreatic Insufficiency Market – (Therapeutic – Pancreatic Enzyme Replacement Therapy (Creon, Zenpep,